Table 2 Baseline characteristics of trial participants
|  | Total (n = 210) | Control (n = 70) | Low dose (n = 70) | High dose (n = 70) |
|---|---|---|---|---|
Age (y), mean (SD) | 65.4 (7.3) | 64.4 (7.4) | 64.7 (8.5) | 67.0 (5.7) |
Female (%) | 46.7 | 47.1 | 50.0 | 42.9 |
Education | ||||
 Primary school or lower (%) | 73.3 | 70.0 | 70.0 | 80.0 |
 Junior high school (%) | 18.1 | 17.1 | 18.6 | 18.6 |
 Senior high school or above (%) | 8.6 | 12.9 | 11.3 | 1.4 |
Past smoker (%) | 44.3 | 44.3 | 40.0 | 48.6 |
Current smoker(%) | 15.2 | 17.1 | 11.4 | 17.1 |
Past drinking (%) | 34.3 | 35.7 | 34.3 | 32.9 |
Current drinking (%) | 4.3 | 2.9 | 2.9 | 7.1 |
Body mass index (kg/m2), mean (SD) | 26.4 (3.4) | 26.5 (3.4) | 25.8 (3.6) | 26.3 (3.1) |
Body weight (kg), mean (SD) | 68.0 (11.1) | 69.1 (11.6) | 67.8 (12.5) | 67.0 (9.0) |
Waist hip ratio (SD) | 0.94 (0.1) | 0.96 (0.06) | 0.94 (0.06) | 0.93 (0.06) |
 Male (SD) | 0.95 (0.1) | 0.97 (0.07) | 0.93 (0.06) | 0.93 (0.06) |
 Female (SD) | 0.93 (0.1) | 0.93 (0.06) | 0.94 (0.06) | 0.93 (0.06) |
Systolic blood pressure (mm Hg), mean (SD) | 147.1 (19.9) | 146.5 (19.9) | 146.5 (21.8) | 146.8 (18.1) |
Diastolic blood pressure (mm Hg), mean (SD) | 84.9 (12.0) | 85.0 (12.9) | 85.0 (12.3) | 84.8 (10.9) |
Medication use | ||||
 Lipid lowering agent (%) | 67.1 | 55.7 | 78.6 | 67.1 |
 Blood pressure lowering agent (%) | 85.2 | 84.3 | 80.0 | 91.4 |
Disease history | ||||
 CVDa(%) | 95.2 | 92.9 | 98.6 | 94.3 |
 Stroke (%) | 31.0 | 24.3 | 25.7 | 42.9 |
 Transient ischemic attack (%) | 29.5 | 21.4 | 21.4 | 45.7 |
 Ischemic heart disease (%) | 81.0 | 78.6 | 90.0 | 74.3 |
 Congestive heart failure (%) | 10.5 | 8.6 | 8.6 | 14.3 |
 Peripheral arterial disease (%) | 7.6 | 8.6 | 5.7 | 8.6 |
 Hypertension (%) | 83.3 | 81.4 | 80.0 | 88.6 |
 Diabetes mellitus (%) | 31.4 | 34.3 | 30.0 | 30.0 |